Drug Profile


Alternative Names: Aminopterin sodium

Latest Information Update: 01 Oct 2013

Price : $50

At a glance

  • Originator ILEX Oncology Inc
  • Developer Genzyme Oncology
  • Class Benzamides; Glutamates; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Endometrial cancer; Leukaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2010 No development reported - Phase-II for Endometrial cancer in USA (PO)
  • 31 Dec 2010 No development reported - Phase-II for Leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top